Thomas Areschoug
Corporate Officer/Principal presso XINTELA AB
Profilo
Thomas Areschoug was the founder of Minervax ApS, a company founded in 2010 where he held the title of Director.
He is currently working as the Chief Business Officer at Xintela AB since 2017.
In the past, he worked as the Manager-Business Development at Invest in Skane AB.
Posizioni attive di Thomas Areschoug
Società | Posizione | Inizio |
---|---|---|
XINTELA AB | Corporate Officer/Principal | 01/03/2017 |
Precedenti posizioni note di Thomas Areschoug
Società | Posizione | Fine |
---|---|---|
Invest in Skane AB
Invest in Skane AB Miscellaneous Commercial ServicesCommercial Services Invest in Skane AB provides organization consulting services. The private company is based in Skane, Sweden. | Corporate Officer/Principal | - |
Minervax ApS
Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark. | Founder | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
XINTELA AB | Health Technology |
Aziende private | 2 |
---|---|
Invest in Skane AB
Invest in Skane AB Miscellaneous Commercial ServicesCommercial Services Invest in Skane AB provides organization consulting services. The private company is based in Skane, Sweden. | Commercial Services |
Minervax ApS
Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark. | Health Technology |
- Borsa valori
- Insiders
- Thomas Areschoug